ARCT
Price
$7.78
Change
-$0.35 (-4.31%)
Updated
Nov 13, 04:59 PM (EDT)
Capitalization
221.05M
Intraday BUY SELL Signals
RZLT
Price
$9.95
Change
-$0.05 (-0.50%)
Updated
Nov 13, 04:59 PM (EDT)
Capitalization
927.28M
90 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ARCT vs RZLT

Header iconARCT vs RZLT Comparison
Open Charts ARCT vs RZLTBanner chart's image
Arcturus Therapeutics Holdings
Price$7.78
Change-$0.35 (-4.31%)
Volume$13.54K
Capitalization221.05M
Rezolute
Price$9.95
Change-$0.05 (-0.50%)
Volume$174.82K
Capitalization927.28M
ARCT vs RZLT Comparison Chart in %
ARCT
Daily Signal:
Gain/Loss:
RZLT
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ARCT vs. RZLT commentary
Nov 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARCT is a Hold and RZLT is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 14, 2025
Stock price -- (ARCT: $8.13 vs. RZLT: $10.00)
Brand notoriety: ARCT and RZLT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARCT: 83% vs. RZLT: 119%
Market capitalization -- ARCT: $221.05M vs. RZLT: $922.64M
ARCT [@Biotechnology] is valued at $221.05M. RZLT’s [@Biotechnology] market capitalization is $922.64M. The market cap for tickers in the [@Biotechnology] industry ranges from $110.25B to $0. The average market capitalization across the [@Biotechnology] industry is $2.1B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARCT’s FA Score shows that 0 FA rating(s) are green whileRZLT’s FA Score has 0 green FA rating(s).

  • ARCT’s FA Score: 0 green, 5 red.
  • RZLT’s FA Score: 0 green, 5 red.
According to our system of comparison, RZLT is a better buy in the long-term than ARCT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARCT’s TA Score shows that 5 TA indicator(s) are bullish while RZLT’s TA Score has 4 bullish TA indicator(s).

  • ARCT’s TA Score: 5 bullish, 5 bearish.
  • RZLT’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both ARCT and RZLT are a good buy in the short-term.

Price Growth

ARCT (@Biotechnology) experienced а -5.90% price change this week, while RZLT (@Biotechnology) price change was +6.95% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.51%. For the same industry, the average monthly price growth was -3.12%, and the average quarterly price growth was +61.90%.

Reported Earning Dates

RZLT is expected to report earnings on Feb 11, 2026.

Industries' Descriptions

@Biotechnology (+1.51% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RZLT($927M) has a higher market cap than ARCT($221M). RZLT YTD gains are higher at: 104.082 vs. ARCT (-52.092). ARCT has higher annual earnings (EBITDA): -54.54M vs. RZLT (-77.12M). ARCT has more cash in the bank: 196M vs. RZLT (86.9M). RZLT has less debt than ARCT: RZLT (1.78M) vs ARCT (27M). ARCT has higher revenues than RZLT: ARCT (110M) vs RZLT (0).
ARCTRZLTARCT / RZLT
Capitalization221M927M24%
EBITDA-54.54M-77.12M71%
Gain YTD-52.092104.082-50%
P/E RatioN/AN/A-
Revenue110M0-
Total Cash196M86.9M226%
Total Debt27M1.78M1,521%
FUNDAMENTALS RATINGS
ARCT vs RZLT: Fundamental Ratings
ARCT
RZLT
OUTLOOK RATING
1..100
5817
VALUATION
overvalued / fair valued / undervalued
1..100
52
Fair valued
40
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9598
PRICE GROWTH RATING
1..100
9636
P/E GROWTH RATING
1..100
99100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RZLT's Valuation (40) in the null industry is in the same range as ARCT (52) in the Pharmaceuticals Major industry. This means that RZLT’s stock grew similarly to ARCT’s over the last 12 months.

RZLT's Profit vs Risk Rating (100) in the null industry is in the same range as ARCT (100) in the Pharmaceuticals Major industry. This means that RZLT’s stock grew similarly to ARCT’s over the last 12 months.

ARCT's SMR Rating (95) in the Pharmaceuticals Major industry is in the same range as RZLT (98) in the null industry. This means that ARCT’s stock grew similarly to RZLT’s over the last 12 months.

RZLT's Price Growth Rating (36) in the null industry is somewhat better than the same rating for ARCT (96) in the Pharmaceuticals Major industry. This means that RZLT’s stock grew somewhat faster than ARCT’s over the last 12 months.

ARCT's P/E Growth Rating (99) in the Pharmaceuticals Major industry is in the same range as RZLT (100) in the null industry. This means that ARCT’s stock grew similarly to RZLT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARCTRZLT
RSI
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
86%
MACD
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
88%
Advances
ODDS (%)
Bullish Trend 4 days ago
79%
Bullish Trend 7 days ago
89%
Declines
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 10 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
ARCT
Daily Signal:
Gain/Loss:
RZLT
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AUIAX37.470.09
+0.24%
AB Equity Income A
MAIPX16.450.02
+0.12%
MAI Managed Volatility Institutional
TSMNX16.960.02
+0.12%
Nuveen Quant Small/Mid Cap Eq I
MISEX43.850.02
+0.05%
Midas Special Opportunities
FIAGX23.19N/A
N/A
Fidelity Advisor International Growth A

ARCT and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARCT has been loosely correlated with ALEC. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if ARCT jumps, then ALEC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARCT
1D Price
Change %
ARCT100%
-6.23%
ALEC - ARCT
59%
Loosely correlated
-1.47%
AXON - ARCT
49%
Loosely correlated
-0.47%
CLDX - ARCT
44%
Loosely correlated
-0.49%
VCYT - ARCT
42%
Loosely correlated
-0.84%
RGNX - ARCT
42%
Loosely correlated
+0.43%
More

RZLT and

Correlation & Price change

A.I.dvisor indicates that over the last year, RZLT has been loosely correlated with SYRE. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if RZLT jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RZLT
1D Price
Change %
RZLT100%
-0.40%
SYRE - RZLT
42%
Loosely correlated
+0.34%
CRVS - RZLT
40%
Loosely correlated
+0.12%
ARCT - RZLT
40%
Loosely correlated
-6.23%
IDYA - RZLT
40%
Loosely correlated
-0.19%
NRIX - RZLT
39%
Loosely correlated
-5.37%
More